Pinnacle Wealth Planning Services Inc. Has $1.11 Million Position in Johnson & Johnson (NYSE:JNJ)

Pinnacle Wealth Planning Services Inc. trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 37.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,651 shares of the company's stock after selling 4,618 shares during the period. Pinnacle Wealth Planning Services Inc.'s holdings in Johnson & Johnson were worth $1,107,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Tallon Kerry Patrick acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $290,000. Capital & Planning LLC boosted its holdings in Johnson & Johnson by 13.6% during the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock worth $221,000 after purchasing an additional 183 shares during the last quarter. Cetera Trust Company N.A grew its position in Johnson & Johnson by 13.5% in the fourth quarter. Cetera Trust Company N.A now owns 1,923 shares of the company's stock valued at $278,000 after purchasing an additional 229 shares in the last quarter. Westside Investment Management Inc. lifted its position in Johnson & Johnson by 13.3% during the 4th quarter. Westside Investment Management Inc. now owns 4,859 shares of the company's stock worth $703,000 after buying an additional 570 shares in the last quarter. Finally, Kelleher Financial Advisors boosted its stake in shares of Johnson & Johnson by 2.6% during the 4th quarter. Kelleher Financial Advisors now owns 6,516 shares of the company's stock worth $942,000 after buying an additional 165 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded up $0.52 during trading hours on Thursday, hitting $152.95. The company had a trading volume of 2,353,932 shares, compared to its average volume of 7,931,169. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The firm has a market cap of $368.02 billion, a PE ratio of 23.00, a PEG ratio of 2.56 and a beta of 0.42. The firm has a 50-day moving average of $154.63 and a 200 day moving average of $153.64. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.40%. Johnson & Johnson's dividend payout ratio is 57.84%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent research reports. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Raymond James decreased their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.